Figure 2.

Use of (A) selected classes of lipid-lowering therapies and (B) statins in the CHD cohort. Percentages reflect the inclusion of all treated patients (n = 457) in panel (A), and all statin-treated patients (monotherapy or combination therapy, n = 454) in panel (B). The ‘other non-statin’ treatments in panel (A) included fibrates, omega- 3 fatty acids, and any other non-statin therapy (except ezetimibe). The ‘other’ treatment in panel (B) included pitavastatin and fluvastatin.

CHD – coronary heart disease.